Oncotarget

Meta-Analysis:

The prognostic value of p62 in solid tumor patients: a meta-analysis

Haihua Ruan, Jingyue Xu, Lingling Wang, Zhenyu Zhao, Lingqin Kong, Bei Lan and Xichuan Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:4258-4266. https://doi.org/10.18632/oncotarget.23101

Metrics: PDF 1108 views  |   HTML 2218 views  |   ?  


Abstract

Haihua Ruan1,*, Jingyue Xu2,*, Lingling Wang3,*, Zhenyu Zhao4,*, Lingqin Kong5, Bei Lan3 and Xichuan Li1,3

1Tianjin Key Laboratory of Food Science and Biotechnology, College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, China

2Department of Clinical Laboratory, The Fifth Central Hospital of Tianjin, Tianjin, China

3School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

4Department of Pharmacy, Tianjin Medical University Metabolic Disease Hospital, Tianjin, China

5Jining Tumor Hospital, Jining No.1 People's Hospital North Campus, Shandong, China

*These authors contributed equally to this work

Correspondence to:

Xichuan Li, email: [email protected]

Haihua Ruan, email: [email protected]

Keywords: solid tumors; p62; prognosis; meta-analysis

Received: October 11, 2017     Accepted: November 16, 2017     Published: December 07, 2017

ABSTRACT

p62, as a scaffolding/adaptor protein, is involved in multiple physiological processes include inflammation, autophagy and mitosis. However, the influence of p62 in cancer patients has not been comprehensively investigated. Moreover, the prognostic value of p62 for the survival of patients with solid tumors remains controversial. In this present meta-analysis, twenty suitable articles were identified from PubMed, EMBASE and Web of Science, Nature databases, including 4271 patients. A random-effect or fixed-effect model was adopted to correlate p62 expression with different outcome measured in entire tumors. Combined with results of hazard ratios (HRs) and 95% confidence intervals (CIs), we concluded that higher expression of p62 is associated with poorer overall survival (OS) (HR: 2.22, 95% CI: 1.82–2.71, P < 0.05), disease-free survival (DFS) (HR = 2.48, 95% CI: 1.78–3.46, P < 0.05) and even certain clinicopathological parameters, such as lymph node metastasis (RR = 1.21, 95% CI: 1.06–1.37) and clinical stages (RR = 1.27, 95% CI: 1.12–1.45), in cancer patients. Consequently, our data showed that p62 might be an effective poor prognostic factor for patients with various solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23101